Tags

Type your tag names separated by a space and hit enter

Psychopharmacologic management of serious behavioral disturbance in ASD.
Child Adolesc Psychiatr Clin N Am. 2014 Jan; 23(1):73-82.CA

Abstract

Individuals diagnosed with autism spectrum disorders (ASD) often exhibit serious behavioral disturbance (irritability) including severe tantrums, aggression, and self-injury that requires pharmacologic management. Research focused on the treatment of severe irritability has primarily involved the atypical antipsychotics, including risperidone and aripiprazole. Anticonvulsants have also been investigated for targeting serious behavioral disturbance; however findings have been mixed. Advances in the pharmacotherapy of irritability in ASD continue to inform practice. Research is needed to develop safer and more effective drug treatments for serious behavioral disturbance in this population.

Links

Publisher Full Text
linkinghub.elsevier.com
journals.elsevierhealth.com
Aggregator Full Text
Aggregator Full Text

Authors+Show Affiliations

Stigler KA
Department of Psychiatry, Christian Sarkine Autism Treatment Center, Indiana University School of Medicine, Riley Hospital for Children, Room 4300, 705 Riley Hospital Drive, Indianapolis, IN 46202-5200, USA. Electronic address: kstigler@iupui.edu.

MeSH

Adrenergic alpha-2 Receptor AgonistsAggressionAnticonvulsantsAntimanic AgentsAntipsychotic AgentsChild Development Disorders, PervasiveClinical Trials as TopicCombined Modality TherapyHumansIrritable MoodSelf-Injurious Behavior

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24231168

Citation

Stigler, Kimberly A.. "Psychopharmacologic Management of Serious Behavioral Disturbance in ASD." Child and Adolescent Psychiatric Clinics of North America, vol. 23, no. 1, 2014, pp. 73-82.
Stigler KA. Psychopharmacologic management of serious behavioral disturbance in ASD. Child Adolesc Psychiatr Clin N Am. 2014;23(1):73-82.
Stigler, K. A. (2014). Psychopharmacologic management of serious behavioral disturbance in ASD. Child and Adolescent Psychiatric Clinics of North America, 23(1), 73-82. https://doi.org/10.1016/j.chc.2013.07.005
Stigler KA. Psychopharmacologic Management of Serious Behavioral Disturbance in ASD. Child Adolesc Psychiatr Clin N Am. 2014;23(1):73-82. PubMed PMID: 24231168.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Psychopharmacologic management of serious behavioral disturbance in ASD. A1 - Stigler,Kimberly A, Y1 - 2013/09/14/ PY - 2013/11/16/entrez PY - 2013/11/16/pubmed PY - 2014/6/24/medline KW - Aggression KW - Autism KW - Autism spectrum disorders KW - Irritability KW - Psychopharmacology KW - Self-injury SP - 73 EP - 82 JF - Child and adolescent psychiatric clinics of North America JO - Child Adolesc Psychiatr Clin N Am VL - 23 IS - 1 N2 - Individuals diagnosed with autism spectrum disorders (ASD) often exhibit serious behavioral disturbance (irritability) including severe tantrums, aggression, and self-injury that requires pharmacologic management. Research focused on the treatment of severe irritability has primarily involved the atypical antipsychotics, including risperidone and aripiprazole. Anticonvulsants have also been investigated for targeting serious behavioral disturbance; however findings have been mixed. Advances in the pharmacotherapy of irritability in ASD continue to inform practice. Research is needed to develop safer and more effective drug treatments for serious behavioral disturbance in this population. SN - 1558-0490 UR - https://www.unboundmedicine.com/medline/citation/24231168/Psychopharmacologic_management_of_serious_behavioral_disturbance_in_ASD_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1056-4993(13)00061-8 DB - PRIME DP - Unbound Medicine ER -